10 results about "Dyskinesia" patented technology

The application relates to the medical technical field, in particular to application of neoline in treatment of Parkinson's disease. 19 The C 19 The type-II diterpene alkaloid neoline can significantly improve movement disorder in a MPTP-induced Parkinson's disease model mouse, the drug efficacy is equivalent to that of the positive drug madopar, the effective dose is much lower than that of the positive drug, the administration mode is oral administration, drug compliance and use convenience are good, and the neoline can be used for development of anti-Parkinson's disease drugs.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The application discloses a Parkinson's disease dyskinesia identification system based on cross-frequency coupling tensor decomposition, comprising: a signal acquisition and processing module, which is used for synchronously collecting local field potential signals of multiple sites of the brain and performing pretreatment; a cross-frequency coupling calculation module, which is used for calculating a cross-frequency coupling atlas of each data segment; a signal-to-noise ratio balance processing module, which is used for generating an average cross-frequency coupling atlas of each subject; a tensor decomposition feature extraction module, which is used for aggregating the average cross-frequency coupling atlas of all subjects, constructing a third-order tensor, and decomposing to obtain three tensor components; and when the average cross-frequency coupling atlas of a to-be-tested subject is input, a weight vector corresponding to the three tensor components is output; and a classification and identification module, which is used for inputting the weight vector of the to-be-tested subject into a pre-trained machine learning classification model, and outputting an identification result of Parkinson's disease dyskinesia. The application can overcome the frequency drift problem existing between different individuals and improve the identification accuracy.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

This document describes a combination composition of compound 1 and fesoterodine for treating neurological disorders (e.g., schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive impairment in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia).

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The present application belongs to the field of life science, and particularly relates to a functional probiotic strain Pediococcus pentosaceus. The Pediococcus pentosaceus WMU002 strain of the present application is derived from human body, and is high in safety after screening, domestication and verification. The Pediococcus pentosaceus WMU002 strain selected by the present application can obviously improve the motor disorder caused by Parkinson's disease and improve the behavior ability, overcome the defects and deficiencies of the prior art, and creatively apply the Pediococcus pentosaceus to the prevention and treatment of Parkinson's disease, and further develop a probiotic preparation for preventing or treating Parkinson's disease. The Pediococcus pentosaceus preparation composition of the present application can be used as a drug for preventing and treating Parkinson's disease, has no toxic side effects, and can be used for the auxiliary treatment of clinical Parkinson's disease patients. The present application has good social and economic benefits, and is worth popularization and application.

The application relates to the technical field of movement disorder symptom evaluation, and provides a modeling method of a movement disorder symptom quantitative evaluation model, which comprises the following steps: step 100: collecting human action data, and establishing a human action recognition model; step 200: extracting tremor characteristics and movement retardation characteristics of a patient, and performing Pearson correlation analysis; step 300: obtaining gait parameters of the patient; step 400: obtaining a movement disorder characteristic set; step 500: based on a full-connection neural network, a movement disorder symptom quantitative evaluation network is established; the movement disorder symptom quantitative evaluation network is trained by using a movement disorder characteristic training set, the movement disorder symptom quantitative evaluation network is tested by using a movement disorder characteristic test set, and finally, a movement disorder symptom quantitative evaluation model is obtained. The quantitative evaluation model can be used for grading evaluation of the movement disorder symptoms of the patient.